Anticholinergic effect on cognition (AEC) of drugs commonly used in older people by Bishara, Delia et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1002/gps.4507
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Bishara, D., Harwood, D., Sauer, J., & Taylor, D. M. (2016). Anticholinergic effect on cognition (AEC) of drugs
commonly used in older people. International Journal of Geriatric Psychiatry. https://doi.org/10.1002/gps.4507
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
1 
Anticholinergic effect on cognition (AEC) of drugs commonly  
used in older people 
 
Delia Bishara1,2,3 BPharm 
Consultant Pharmacist Mental Health of Older Adults and Dementia  
 
Daniel Harwood2* DM 
Consultant Psychiatrist and Clinical Director Mental Health of Older Adults and Dementia 
Clinical Academic Group 
 
Justin Sauer2 FRCPsych 
Consultant Psychiatrist Mental Health of Older Adults and Dementia Clinical Academic Group 
 
David M Taylor1,3 PhD 
Professor of Psychopharmacology 
 
1. Maudsley Hospital, Pharmacy Department 
Denmark Hill, London SE5 8AZ, UK 
 
2. Mental Health of Older Adults and Dementia Clinical Academic Group,  
South London and Maudsley NHS Foundation Trust, London, UK 
 
3. Institute of Pharmaceutical Science, King’s College, London 
5th Floor, Franklin-Wilkins Building 
150 Stamford Street, London SE1 9NH 
 
*Author for correspondence 
Address: Maudsley Hospital, Pharmacy Department, Denmark Hill, London SE5 8AZ, UK 
Email:  david.taylor@slam.nhs.uk 
Telephone: + 44 20 3228 5040 
 
Running title: Anticholinergic effect on cognition 
Keywords: Dementia, Cognitive Function, Anticholinergic 
Key points: Drugs with anticholinergic action have clear negative effects on cognitive function 
The number of drugs with important central anticholinergic activity is underestimated 
We list sixty drugs commonly used in older patients which have central anticholinergic effects 
Funding: This study received no funding 
2 
Abstract  
Objective 
Use of anticholinergic drugs in older people is associated with increased risk of cognitive 
decline, and of dementia and death.  
 
Method 
We identified drugs widely used in older people and attempted to classify their 
anticholinergic effect on cognition (AEC) according to our 3-point scale which scored AEC 
according to in vitro anticholinergic potency, capacity to cross the blood brain barrier and 
statements made in standard texts.  
 
Results 
In total 165 drugs were examined. We identified 21 drugs with an AEC score of 3, 18 with a 
score of 2, 21 with a score of 1 and 62 with a score of 0.  Owing to insufficient information,   
we were unable to classify 43 drugs. 
 
Conclusions 
A large number of drugs commonly used in the elderly are likely to be associated with 
cognitive impairment.  
 
Declaration of interest 
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BristolMyersSquibb, AstraZeneca, Sunovion and Otsuka. JS, DB and DH declare no potential 
conflicts of interest.  
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Introduction 
“Anticholinergic” drugs block muscarinic receptors and impair cholinergic function. This 
action causes well known peripheral effects but also central adverse effects including 
confusion, disorientation, memory impairment, hallucinations and delirium (Feinberg M 
1993). Long term use of anticholinergic drugs in older people is associated with an increased 
risk of cognitive decline, and of dementia and early death (Carriere I et al., 2009; Fox C et al., 
2011; Gray SL et al., 2015; Jessen F et al., 2010). Anticholinergic drugs also directly oppose 
the action of acetylcholinesterase inhibitors (AChEIs) used in dementia. Despite this, up to 
half of the patients with Alzheimer’s Disease (AD) who are prescribed cholinesterase 
inhibitors are also taking drugs with anticholinergic activity (Carnahan RM et al., 2004; Modi 
A et al., 2009). The concurrent use of the two drug classes predictably and demonstrably 
reduces the clinical efficacy of the cholinesterase inhibitor (Lu CJ and Tune LE 2003; Sink KM 
et al., 2008). Anticholinergic agents may also be implicated in the time to onset of psychotic 
symptoms in patients with AD (Cancelli I et al., 2009).  
 
Five muscarinic receptor subtypes have been identified (M1-M5). The M1 receptor is the most 
abundant subtype in the central nervous system (CNS) and is thought to have a primary role 
in mediating cholinergic effects on cognitive function. M2 receptors are located throughout 
the brain and are involved in memory processes. M4 receptors are abundant in the 
neostriatum and are thought to be involved in the regulation of acetylcholine levels (Kay GG 
et al., 2005; Volpicelli LA and Levey AI 2004). Thus cognitive impairment, in particular 
memory dysfunction, can result from antagonism of M1 and, to some extent, M2 or M4 
receptors in the CNS (Kay GG, bou-Donia MB, Messer WS, Jr., Murphy DG, Tsao JW and 
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Ouslander JG 2005). For an anticholinergic drug to cause cognitive impairment, it must also 
be able to penetrate the blood brain barrier (BBB), and so act centrally.  
 
Whilst some anticholinergic drugs are used specifically for the therapeutic effects of their 
anticholinergic action, other drugs have anticholinergic effects that are secondary to their 
primary mode of action. To assist clinicians in minimising the use of drugs with 
anticholinergic action in people with cognitive impairment various anticholinergic risk scales 
have been produced. These usually comprise a list of drugs with a classification of 
anticholinergic potency listed for each (Duran CE et al., 2013).  Scales have also been 
developed to calculate the total anticholinergic burden for an individual (Boustani M et al., 
2008). There is considerable variation amongst these scales because of differences in scale 
development, selection of drugs and methods of evaluation of anticholinergic potency. In 
addition, factors such as the selectivity of drugs to specific muscarinic receptor subtypes and 
its ability to enter the brain have not always been considered.  
The aim of this review was to produce a scale illustrating the negative anticholinergic effect 
of drugs on cognition using a clear, concise and systematic approach which takes into 
consideration the muscarinic binding affinity of drugs, their selectivity, their penetration into 
the brain and whether or not reports of cognitive impairment exist.  
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Method 
Two authors (DH and DB) reviewed all British National Formulary (BNF) categories in January 
2014 and again in January 2015 to identify and agree upon the main drug classes and 
medicines commonly used in older people in the UK. We included the majority of categories 
of drugs eg those acting on the gastrointestinal, cardiovascular, genitourinary, and central 
nervous systems but excluded specialist drugs such as cytotoxics and hormone treatments 
(except those acting on insulin). Electronic searches using Pubmed, Medline and Embase 
were performed to identify which of these drugs had the potential to affect cognitive 
function using the search terms: “dementia,” “delirium” AND “cognition” or “cognitive 
function” or “cognitive impairment” AND “drugs” or “medication,” followed by the same 
searches using the same terms combined with the specific drug classes and individual drug 
names.  In October 2014, searches using Pubmed and Embase were undertaken to identify 
drugs with known anticholinergic activity. From these searches a list was made of the drugs 
which we deemed to merit further investigation. This list included those drugs noted in the 
literature as potentially affecting cognition and drugs listed in the literature as having 
anticholinergic activity. We also investigated any drug not in these two categories, but which 
the authors agreed were commonly used by older people.  We examined each individual 
drug to determine whether or not they had any reported anticholinergic properties and if so, 
the antimuscarinic potency and specificity to receptor subtypes, whether or not the drug 
penetrated the blood brain barrier and whether or not there were any reports of associated 
cognitive impairment. 
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All drugs generated by these reviews were individually: 
 
1) Entered into the National Institute of Mental Health Psychoactive Drug Screening 
Program (PDSP) Ki database (PDSP K1 Database 2014) of published binding affinities 
(Ki) of drugs for muscarinic receptors, and more specifically for M1, M2 and M4 
receptors. Data for muscarinic M1 (linked to cognitive impaired) binding affinities 
were used in preference to other muscarinic receptor binding affinities where 
available. If drug specificity to the receptor subtypes was not available, general 
muscarinic binding affinity data were used. Anticholinergic activity is measured using 
competitive radioreceptor binding. The compound [3H]quinuclidinyl benzilate 
([3H]QNB) is a specific muscarinic receptor antagonist often used as the radioligand. 
Anticholinergic activity of a drug is based on the amount of [3H]QNB displaced by the 
drug under investigation. Where available, Ki values from competitive radioligand 
binding studies using [3H]QNB in human brain (or cloned human brain) were used.  
 
2) Inputted into Martindale (Pharmaceutical Press 2014), American Hospital Formulary 
Service (AHFS) (American Hospital Formulary Service 2015) and the Summary of 
Product Characteristics (SPC) (DataPharm 2015) to determine whether or not the 
drug was described as having had any anticholinergic properties, and/or penetrated 
the blood brain barrier and/or had been reported to cause cognitive impairment. 
 
3) Searched via Pubmed, Embase and Google scholar to identify muscarinic binding 
affinity, penetration across BBB and any medical literature on anticholinergic 
cognitive adverse effects (where information was not identified from previous steps). 
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Two authors (DB and DH) reviewed the information retrieved. For each drug they 
independently assigned a score of 0, 1, 2 or 3 (or “unable to score”) based on the 
antimuscarinic potency, selectivity of drug to muscarinic receptors, penetration through 
blood brain barrier and reports of cognitive adverse effects. Since other mechanisms may be 
involved in the causation of cognitive impairment besides antimuscarinic effects, reports of 
cognitive impairment were used as confirmation and to validate our scoring system, rather 
than to aid assignment of scores.  If a drug was known to cross the BBB and had reports of 
cognitive impairment, the assigned score would depend on the Ki values for muscarinic 
receptors. If a drug had high antimuscarinic potency but penetrated the brain poorly then its 
AEC score was reduced accordingly (see Table 1). Where no initial agreed decision could be 
reached between the two authors, this was resolved by asking the 3rd and 4th authors (JS and 
DT) to independently score the drug, and then the mode of the scores was used.  
 
Table 1- Assignment of scores for individual drugs 
There were two steps in assigning the antimuscarinic score.  First, the antimuscarinic activity 
was assessed using the table below, and then the score was refined according to the degree 
of penetration into the blood-brain barrier by the drug. 
If there were no Ki data available and no published reports of clinical or in vitro 
antimuscarinic activity, a score could was not assigned.  
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Refining the score according to degree of penetration of the blood brain barrier 
If there was evidence that the drug or its active metabolites readily penetrated the BBB from 
either published data on cerebrospinal fluid (CSF) drug levels or published evidence of 
clinical effects indicating well described central actions (e.g. frequent sedation or 
neuropsychiatric symptoms) the score assigned remained unchanged. 
If there was published evidence that for a drug or its metabolites, penetration across the 
BBB is known to be limited in some way, or there was published evidence of weak or limited 
central effects (e.g. infrequent reports of only mild neuropsychiatric symptoms) the score 
was downgraded by one point.  
If there was published evidence that a drug or its metabolites had little or no penetration 
across the BBB, or there was published research demonstrating the absence of central 
effects, no reports of neuropsychiatric symptoms in clinical studies of the drug and no 
research suggesting of any central anticholinergic effects, a score of 0 was assigned. 
 
Table 2- Level of evidence available 
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Results  
Our searches identified several publications quantifying the antimuscarinic effects of drugs 
which were not included in the PDSP Ki database.  These included some antihistamines 
(Kubo N et al., 1987; Liu H and Farley JM 2005), antipsychotics (Chew ML et al., 2006; Hals 
PA et al., 1988), antidepressants (El-Fakahany E and Richelson E 1983; Nomura S et al., 1987; 
Rudd KM et al., 2005), bladder anticholinergics (Ohtake A et al., 2007), certain opioids 
(Hustveit O 1994) and some other medicines commonly used by older adults (Chew ML et 
al., 2008). These drugs were included in our evaluations giving a total of 165 drugs assessed. 
For many of the drugs on the list, information regarding penetration into the brain was 
determined from Martindale (Pharmaceutical Press 2014), the SPC (DataPharm 2015) or 
AHFS (American Hospital Formulary Service 2015). For the others, we used information 
retrieved from primary or secondary references uncovered by electronic searches (Basak SC 
et al., 1996; Crivori P et al., 2000; Di L et al., 2003).  
 
Table 3 displays the anti-muscarinic score calculated by the method described above for the 
list of drugs chosen for evaluation. Of the 165 drugs reviewed, there was disagreement 
between the first 2 authors on 9 drugs (5%), for which the opinions of the 3rd and 4th authors 
were then sought independently. In all, 21 drugs received a score of 3; 18 a score of 2, 21 a 
score of 1 and 62 drugs were given a score of zero.  There were insufficient data to score a 
further 43 drugs.   
 
Table 3 
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There was no clear information available on whether or not benzodiazepines were 
anticholinergic. It appears that although benzodiazepines do not bind to muscarinic 
receptors, chronic treatment changes both the number and affinity for the muscarinic 
receptors in the brain. Benzodiazepines might therefore directly or indirectly influence 
muscarinic receptors (Nordberg A and Wahlstrom G 1992). In general, benzodiazepines are 
best avoided in patients with dementia. Lorazepam is short acting and because it is less lipid 
soluble than other benzodiazepines, it penetrates the brain more slowly (Tedeschi G et al., 
1983) causing fewer cognitive adverse effects.     
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Discussion 
We assessed over 165 drugs commonly used in older people and found 60 of them to have 
clear capacity to impair cognitive function to varying degrees. Our assessment method is 
perhaps more transparent than previously described methods and we have evaluated a 
larger number of drugs.  Before, the only readily available means for discovering the 
antimuscarinic activity of drugs has been to consult one of the existing lists of drugs with 
anticholinergic properties. (American Geriatrics Society 2012 and Beers Criteria Update 
Expert Panel 2012; Boustani M, Campbell N, Munger S, Maidment I and Fox C 2008; Han L et 
al., 2001) These lists were mostly developed using subjective ratings of anticholinergic 
activity based on clinical experience of the drugs and observed cognitive impairment. These 
lists were effectively consensus statements (Rudd KM, Raehl CL, Bond CA, Abbruscato TJ and 
Stenhouse AC 2005) and did not list drugs not considered to have anticholinergic activity 
leaving some ambiguity as to whether drugs not mentioned had no anticholinergic activity, 
or were simply not evaluated. Furthermore, whilst many of the lists rated drugs on the basis 
of their anticholinergic potency, they did not always take into account whether or not the 
drug was selective for the target tissue or organ or to what extent it penetrated the blood 
brain barrier and was therefore likely to cause CNS effects. Our transparent and systematic 
approach to developing an explicit systematic AEC Scale took these limitations into 
consideration. It also minimised subjective rating by clinicians (which may vary based on 
knowledge and experience) by independently rating drugs using strict criteria and evidence-
based data.  
 
A limitation of this paper is the incomplete availability of dissociation constant (Ki) values 
and therefore our inability to accurately score many drugs. Similarly, where there were 
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conflicting data on whether or not a drug was actually anticholinergic, we were unable to 
assign a score. For some classes of drugs, there was sufficient data to rate some drugs but 
not others in the same class. Other limitations relate to the fact that the level of evidence for 
antimuscarinic activity data available to us was somewhat variable (see Table 2). Many of 
our assessments were at least partly based on in vitro antimuscarinic activity.  In vitro use of 
radio-receptor assay does not account for varying drug dosages (measured in mass units 
rather than moles), pharmacokinetics or differences due to individual patient physiology. 
Similarly BBB penetration is variable and can be affected by age, gender and other factors 
including dementia (Chancellor MB et al., 2012; van Assema DM et al., 2012).  In addition, 
recent work in human-derived neurons and astrocytes suggests that there is not a linear 
relationship between anticholinergic polypharmacy and in vivo effects, suggesting that 
current scales may underestimate the effect of polypharmacy (Woehrling EK et al., 2015). 
Also, because other neurotransmitter systems are also involved in cognitive function, there 
may be drugs with an AEC score of 0 on this scale, which still affect cognition through other 
modes of action.  Finally, our method, while transparent and systematic, remains effectively 
a consensus view, albeit based on published data. 
 
We aimed to evaluate drugs commonly used in older people so that our results would be of 
use to clinicians in community or hospital settings.  However it is not a comprehensive list of 
drugs, and absence of a drug from the list does not imply the drug has no anticholinergic 
activity. We have not included drugs which are only used in very specialist situations (such as 
cytotoxic drugs) or where use is generally confined to hospital settings (such as anaesthetic 
agents).  
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Since the risk of cognitive impairment, incident dementia and early death has been linked to 
the cumulative use of anticholinergic drugs (Fox C, Richardson K, Maidment ID, Savva GM, 
Matthews FE, Smithard D, Coulton S, Katona C, Boustani MA and Brayne C 2011; Gray SL, 
Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, Yu O, Crane PK and Larson EB 
2015), it is obviously good practice to use drugs with AEC scores of zero and to avoid those 
scored 1,2 or 3. All individual drugs with an AEC score of 2 or 3 in older people presenting 
with symptoms of cognitive impairment, dementia or delirium should be withdrawn as these 
drugs have unequivocal anticholinergic action and central adverse effects. The clinician 
should discuss with the patient and carer the benefits and potential risks of continued use of 
these drugs with the aim of either stopping them or switching to an alternative drug with a 
lower AEC score (preferably zero). In patients who are not receiving any medication with an 
AEC score of 2 or 3 but who have a total AEC score above 3, a similar patient-clinician review 
should take place. If withdrawal of a drug is deemed appropriate, this should follow a 
gradual schedule to avoid rebound anticholinergic effects (Boustani M, Campbell N, Munger 
S, Maidment I and Fox C 2008).  
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Conclusion 
We have been able to evaluate and rate 122 drugs for anticholinergic effect on cognition 
using a systematic method of assessment.  Half of the drugs evaluated are likely to induce 
cognitive impairment to some degree and should normally be avoided in older people.  The 
long term aim for researchers in this area should be to produce an internationally recognised 
single unified scale of clinically relevant anticholinergic activity covering all licenced 
medications which has been validated in clinical settings. We are some way off this, but we 
hope that this paper, even though it has significant limitations, by covering a larger number 
of drugs, and by incorporating all available evidence for anticholinergic burden of drugs, is a 
step in the right direction. We hope researchers will take up the challenge and now assess 
the utility of the scale in clinical settings. 
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Table 1- Assignment of scores for individual drugs 
Description 
of criteria 
 
 
 
 
 
 
 
Ki >10,000 nM 
or 
Published in 
vitro data 
showing no  
antimuscarinic 
activity  
or  
comment in 
Martindale or 
SPC stating no 
antimuscarinic 
effects 
Ki 1,001-10,000 nM 
or 
Published in vitro 
data showing 
minimal or 
equivocal 
antimuscarinic 
action 
or 
comment in 
Martindale or SPC 
stating minimal, 
weak or mild 
antimuscarinic 
effects 
Ki 100-1,000 nM 
or 
Published in vitro 
data showing 
moderate 
antimuscarinic 
effects 
or 
comment in 
Martindale or SPC 
stating some or 
moderate  
antimuscarinic 
effects 
Ki <100 nM 
or 
Published in vitro 
data showing 
strong 
antimuscarinic 
effects 
or 
comment in 
Martindale or SPC 
stating strong  
antimuscarinic 
effects 
None of 
these 
data 
available  
Anti-
muscarinic 
score  
0 1 2 3 Not 
known  
(This table must be used in conjunction with the methods described).
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Table 2- Level of evidence available 
Level of evidence Information available 
Level 1 Ki value for M1 receptor binding available in 
human (or cloned human) brain 
 
Level 2 Ki value for muscarinic receptor binding 
(non-specific) or Ki value for muscarinic 
binding in rodent brain 
 
Level 3 Comment in Martindale or SPC or other 
publication stating whether drug has 
anticholinergic properties or not 
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 Table 3 Anticholinergic effect on Cognition (AEC) scores 
 
 
Limited data so unable to score Drugs with AEC score of 0 Drugs with AEC 
score of 1 
Drugs with AEC score of 2 Drugs with AEC score of 3 
Alendronic Acid Ramipril Alprazolam Lovastatin Amiodarone Amantadine Alimemazine (trimeprazine) 
Allopurinol Rivaroxaban Amlodipine Lurasidone Aripiprazole Chlorphenamine Amitriptyline 
Anastrozole Rosuvastatin Amoxycillin Meloxicam Bromocriptine Desipramine Atropine 
Apixaban Spironolactone Aspirin Metoclopramide Carbamazepine Dicycloverine (dicyclomine) Benztropine 
Baclofen Tamoxifen Atenolol Metoprolol Citalopram Dimenhydrinate Chlorpromazine 
Bisoprolol Topiramate Atorvastatin Moclobemide Diazepam Diphenhydramine Clemastine 
Bumetanide Tizanidine Buproprion Morphine Domperidone Disopyramide Clomipramine 
Captopril Verapamil Cepahlexin Naproxen Fentanyl Levomepromazine (methotrimeprazine) Clozapine 
Carbimazole Zopiclone Cetirizine Omeprazole Fluoxetine Olanzapine Cyproheptadine 
Carvedilol Zotepine* Chlordiazepoxide Paracetamol Fluphenazine Paroxetine Dothiepin 
Chlortalidone  Cimetidine Pantoprazole Hydroxyzine Pethidine Doxepin 
Clarithromycin  Ciprofloxacin Pravastatin Iloperidone Pimozide Hyoscine hydrobromide 
Clonazepam  Clopidogrel Propranolol Lithium Prochlorperazine Imipramine 
Codeine  Darifenacin Rabeprazole Mirtazapine Promazine Lofepramine 
Colchicine  Diclofenac Ranitidine Perphenazine Propantheline Nortriptyline 
Dabigatran  Diltiazem Risperidone Prednisolone Quetiapine Orphenadrine 
Dexamethasone  Enalapril Rosiglitazone Quinidine Tolterodine Oxybutynin 
Dextropropoxyphene  Entacapone Simvastatin Sertindole Trifluoperazine Procyclidine 
Digoxin  Fexofenadine Theophylline Sertraline  Promethazine 
Erythromycin  Fluvoxamine Thyroxine Solifenacin  Trihexyphenidryl (benzhexol) 
Flavoxate*  Furosemide Tramadol Temazepam  Trimipramine 
Hydrocodone  Gabapentin Trazodone    
Irbesartan  Gliclazide Trimethoprim    
Lansoprazole  Haloperidol Trospium    
Levetiracetam  Ibuprofen Venlafaxine    
Metformin  Ketorolac Valproate    
Methocarbamol  Lamotrigine Warfarin    
Methotrexate  Levadopa Ziprasidone    
Nitrofurantoin  Lisinopril Zolpidem    
Oxcarbazepine  Loperamide     
Oxycodone  Loratadine     
Phenytoin  Lorazepam     
Pregabalin  Losartan     
 
3 - review and withdraw or switch 
 
2 - review and withdraw or switch 
 
1 - caution required 
  
0 – safe to use 
 
* These drugs have confirmed anticholinergic activity but the extent and clinical significance of this is unknown. 
